Table 3.

The half-maximal inhibitory concentrations (IC₅₀) of the 3-Chloro-4-[(4-methoxyphenyl)amino]furo[2,3-b]quinoline (PK-L4) solution and PK-L4-loaded solid lipid nanoparticles (SLNs) with and without polyethylene glycol (PEG) monostearate

Formulations	IC50 (μg/mL) on cell lines
	A549	HepG2	MCF7	MDA-MB-231	Ca9-22
PK-L4 solution	0.11	0.04	8.47	2.14	0.04
SLNs without PEG	0.06	0.09	0.10**	0.11**	0.03
SLNs with PEG	0.04*	0.04	0.10**	0.12**	0.03
Doxorubicin solution	0.40*	0.11*	0.43**	0.51**	0.14*

Notes: A doxorubicin solution was used as the comparison group. Each value represents the mean ± standard deviation (n = 6).

^*P < 0.05;

^**P < 0.01 as compared with the data of PK-L4 control solution. Note that doxorubicin solution was a free aqueous solution – this drug has commercial potential as an anticancer drug.

Abbreviations: A549, human lung carcinoma cell line; HepG2, human hepatocellular liver carcinoma cell line; MCF7, human breast adenocarcinoma with estrogen receptor cell line; MDA-MB-231, human breast adenocarcinoma cell line; Ca9-22, human oral squamous cell carcinoma cell line.